Simoa® accelerator laboratory

With the Simoa® Accelerator Laboratory as your pharma service technology solution of choice, you can expand the limits of biomarker exploration and dramatically accelerate the timeline to drug approvals.

request more info

SIMOA® in Action

Learn how we advance access to the biology of the brain

see related case study

Our Culture

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health.

The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.

How it Works

Simoa, an ultra-sensitive immunoassay technology allows detection of proteins and nucleic acids at lowest possible levels.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor. Sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nam fermentum, nulla luctus pharetra vulputate, felis tellus mollis orci, sed rhoncus pronin sapien nunc accuan eget.The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead.

  • Paramagnetic particles coupled with antibodies designed to bind to specific targets are added to the sample.
  • Detection antibodies – capable of generating fluorescent product – are added.
  • The objective is to form an immunocomplex consisting of the bead, bound protein, and detection antibody.
  • At low concentrations, each bead will contain one bound protein, or none.
  • The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead.

Work With Us

Section without icons on the right and with CTA below text here

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor. Sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nam fermentum, nulla luctus pharetra vulputate, felis tellus mollis orci, sed rhoncus pronin sapien nunc accuan eget.The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead.

Field Applications Scientists

  • Paramagnetic particles coupled with antibodies designed to bind to specific targets are added to the sample.
  • Detection antibodies – capable of generating fluorescent product – are added.
  • The objective is to form an immunocomplex consisting of the bead, bound protein, and detection antibody.
  • At low concentrations, each bead will contain one bound protein, or none.
  • The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead.

Detecting the Undetectable

Simoa, an ultra-sensitive immunoassay technology allows detection of proteins and nucleic acids at lowest possible levels.

First of its kind detection capabilities

This innovative technology is perfectly suited for single- and multi-plex detection of key biomarkers at ultra-low levels in applications within all therapeutic areas, including oncology, neurology, cardiology, immunology, and infectious disease.

Detect biomarkers at femtogram levels

The innovative digital nature of the technique allows an average of 1000 times sensitivity increase over conventional assays, with CVs less than 10 percent.

See results in record time

Incubation time for analyte capture and detector binding is typically about 30 minutes, with five minutes for labeling by the streptavidin β-galactosidase (SBG) conjugate.

Benefits of Working With Us

will be replaced with SVG

Health, dental, life insurance

will be replaced with SVG

Flexible spending plan

will be replaced with SVG

Paid vacation

will be replaced with SVG

Stock options

will be replaced with SVG

401(k) investment plan

See Also

Simoa, an ultra-sensitive immunoassay technology allows detection of proteins and nucleic acids at lowest possible levels.

Customer Care

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor.

Meet the Team

Tech Support

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor.

Meet the Team

Field Service Engineer

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor.

Meet the Team

Field Applications Scientists

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor.

Meet the Team

Let Us Tell You

“I was truly amazed by the Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo.”

John Smith, the Corporation Company

“2 I was truly amazed by the Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo.”

John Smith 2, the Corporation Company 2

“3 I was truly amazed by the Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo.”

John Smith 3, the Corporation Company 3

“4 I was truly amazed by the Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo.”

John Smith 4, the Corporation Company 4

services

Quanterix Solutions

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet.

Quanterix Assays

Our broad portfolio of available kits spans multiple therapeutic areas including cardiology, infectious disease, inflammation, neurology, and oncology. Choose from our readily-available kits or our homebrew option.

SIMOA Bead Technology

Simoa means sensitivity. Find out how Quanterix’ Simoa Bead Technology is changing the way in which the biology of health and disease is studied.

learn more

Planar Array Technology

With Simoa Senstivity™, Quanterix’ Planar Array Technology now gives researchers an incredibly simple, flexible, robust, and sensitive multiplex immunoassay platform for measuring biomarkers in most common sample types.

learn more

Uman Diagnostics Assays & Reagents

Our broad portfolio of available kits spans multiple therapeutic areas including cardiology, infectious disease, inflammation, neurology, and oncology. Choose from our readily-available kits or our homebrew option.

SIMOA Bead Technology

Simoa means sensitivity. Find out how Quanterix’ Simoa Bead Technology is changing the way in which the biology of health and disease is studied.

learn more

Planar Array Technology

With Simoa Senstivity™, Quanterix’ Planar Array Technology now gives researchers an incredibly simple, flexible, robust, and sensitive multiplex immunoassay platform for measuring biomarkers in most common sample types.

learn more

Oncology

The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research. Simoa® assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.

see related assays

Neurology

The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed. Simoa assays can detect neurological biomarkers, such as Neurofilament Light (NfL),Tau, GFAP and several otohers associated with brain injury and disease. With Simoa, these informative markers can be detected at much earlier stages, in blood, serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS) and is working with a rapidly growing network of academic researchers & pharmaceutical and biotech partners to drive advancements in head health research.

see related assays

Brain Derived Neurotrophic Factor (BDNF)

Brain Derived Neurotrophic Factor (BDNF) is a member of the neurotrophin family, which includes NGF, NT-3, and NT-4/5. This family is likely derived from a common ancestral gene and share similar sequences and structures.

BDNF has a molecular weight of ~27 kDa and exists as a homodimer. It shares a common cysteine knot structure with the other members of the neurotrophin family. BDNF has a precursor peptide known as proBDNF, and during processing the cleaved pro-domain is packaged and co-secreted with the mature BDNF form. The effects of proBDNF are less defined than those of the mature BDNF form. BDNF’s effects are mostly mediated through the TrkB receptor, though it can also bind to a pan-neurotrophin receptor known as p75. BDNF is associated with almost all aspects of the nervous system, promoting neuronal survival and differentiation, modulating synaptic plasticity, synapse formation, neuronal excitability, LTP, etc. It has important roles within the development of the nervous system into adulthood. Several studies have demonstrated possible links to various disease states and conditions including: Alzheimer’s disease, OCD, depression, Huntington’s disease, schizophrenia and dementia.

SIMOA® Accelerator Lab by the Numbers

0

Customers to Date

0

Samples Run to Date

0

Projects to Date

Total Biomarker Assays

0

Oncology

0

Neurology

0

Immunology

0

Cardiology

0

Infectious Disease

Products Mentioned

Sociis Natoque
Request a Quote
Penatibus Et Magnis
Request a Quote
Dis Parturient Montes
Request a Quote
Nascetur Ridiculus Mus
Request a Quote

Our Mission & Vision

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet

Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor. Sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nam fermentum, nulla luctus pharetra vulputate, felis tellus mollis orci, sed rhoncus pronin sapien nunc accuan eget.

  • Proin gravida dolor sit amet lacus accumsan et viverra justo commodo.
  • Proin sodales pulvinar sic tempor.
  • Sociis natoque penatibus et magnis dis parturient monte.
meet the team

Kevin Hrusovsky

President, Chairman and Chief Executive Officer

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor. Sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nam fermentum, nulla luctus pharetra vulputate.

Ready to take your biomarker research to the next level?

request a quote

Let Us Show You

Simoa® assays by the numbers

Quanterix’ Simoa technology is changing the way in which the biology of health and disease is studied by giving researchers the ability to closely examine critical biomarkers.

In doing so, this game-changing technology enables the development of methods providing much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.

See Also

Simoa, an ultra-sensitive immunoassay technology allows detection of proteins and nucleic acids at lowest possible levels.

Delivering Ultrasensitive Biomarker Measurement

Quanterix is re-engineering ultrasensitivity with the launch of the Simoa HD-X Analyzer™, the latest model fully automated Simoa bead-based immunoassay platform. Leveraging years of experience with the ground-breaking Simoa HD-1 Analyzer, the new flagship HD-X delivers major productivity improvements, greater user flexibility, unparalleled sensitivity, and best-in-class assay performance across a broad assay menu to empower biomarker research and accelerate drug development.

read more

Delivering Ultrasensitive Biomarker Measurement 2

Quanterix 2 is re-engineering ultrasensitivity with the launch of the Simoa HD-X Analyzer™, the latest model fully automated Simoa bead-based immunoassay platform. Leveraging years of experience with the ground-breaking Simoa HD-1 Analyzer, the new flagship HD-X delivers major productivity improvements, greater user flexibility, unparalleled sensitivity, and best-in-class assay performance across a broad assay menu to empower biomarker research and accelerate drug development.

read more

Does your research focus on neuropathy associated with SARS-Cov-2 infection?

Check out the extensive neurology menu on HD-X and SR-X providing the same level of sensitivity and precision as SPX for your cytokine research

Delivering Ultrasensitive Biomarker Measurement You Can Count On.

Quanterix is re-engineering ultrasensitivity with the launch of the Simoa HD-X Analyzer™, the latest model fully automated Simoa bead-based immunoassay platform. Leveraging years of experience with the ground-breaking Simoa HD-1 Analyzer, the new flagship HD-X delivers major productivity improvements, greater user flexibility, unparalleled sensitivity, and best-in-class assay performance across a broad assay menu to empower biomarker research and accelerate drug development.

Ultra-sensitivity

Up to 1000x greater sensitivity than traditional immunoassays

Automation

Reproducibility and convenience of sample-answer workflow

Regulatory Compliance

Enables 21CFR Part 11 compliance with streamlined run reports and user management

Automation

Reproducibility and convenience of sample-answer workflow

Ultra-sensitivity

Up to 1000x greater sensitivity than traditional immunoassays

Automation

Reproducibility and convenience of sample-answer workflow

Video about SIMOA Technology

We are on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. In our focused therapeutic areas, our revolutionary technology is helping researchers advance the science of precision health.

Watch our one minute video

Quanterix’ proprietary Simoa technology is based on the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents.

learn more
Will be replaced with SVG

Watch our one minute video

Quanterix’ proprietary Simoa technology is based on the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents.

learn more

Watch our one minute video

Quanterix’ proprietary Simoa technology is based on the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents.

Watch our one minute video

learn more

Watch our one minute video

Here Goes the Title

Using simple, well-established chemistry, researchers can explore significant unmet needs in life science research using digital biomarker analysis technology.

Using simple, well-established chemistry, researchers can explore significant unmet needs in life science research using digital biomarker analysis technology. Quanterix also provides the option of developing multiplex homebrew assays to minimize the sample volume, providing full kits that include all reagents and training required to develop these custom homebrew assays. The LONGTERMS study evaluated the safety and efficacy of fingolimod in patients with relapsing MS (RMS) with up to 14 years of exposure. This phase IIIb, open-label extension study included patients aged 18 years with confirmed RMS diagnosis who completed previous phase II/III/IIIb core/extension studies of fingolimod.

Conclusion

The LONGTERMS study evaluated the safety and efficacy of fingolimod in patients with relapsing MS (RMS) with up to 14 years of exposure. This phase IIIb, open-label extension study included patients aged 18 years with confirmed RMS diagnosis who completed previous phase II/III/IIIb core/extension studies of fingolimod. Patients received fingolimod 0.5 mg orally once daily; safety and efficacy (clinical and magnetic resonance imaging) were the main outcomes.

SIMOA® Accelerator Laboratory

Greater depths of contract research at your reach

With the Simoa® Accelerator Laboratory as your pharma service technology solution of choice, you can expand the limits of biomarker exploration and dramatically accelerate the timeline to drug approvals.

The SIMOA Accelerator Laboratory

  • CLIA-Certified Laboratory
  • Offers the technology for single-plex and multiplex detection
  • Infrastructure allows scalability to handle sample sets
  • Develops robust SOPs and LIMS for project/sample tracking
  • Delivers quick turn-around with the flexibility to adjust project scope
  • Onsite assay development training through a 4-day program

SIMOA® Accelerator Laboratory

Greater depths of contract research at your reach

With the Simoa® Accelerator Laboratory as your pharma service technology solution of choice, you can expand the limits of biomarker exploration and dramatically accelerate the timeline to drug approvals.

The SIMOA Accelerator Laboratory

  • CLIA-Certified Laboratory
  • Offers the technology for single-plex and multiplex detection
  • Infrastructure allows scalability to handle sample sets
  • Develops robust SOPs and LIMS for project/sample tracking
  • Delivers quick turn-around with the flexibility to adjust project scope
  • Onsite assay development training through a 4-day program

contact us

900 Middlesex Turnpike, Building 1 Billerica, MA 01821 USA

+1 (617) 301-9400

see detailed contact info

Our International Distributors

Japan

ffsdfsdf
Tel: 2352352352Fax: 324243235253

Singapur

asdasdasd
Tel: adsasd

Kevin Hrusovsky

Chairman and Chief Executive Officer


Masoud Toloue, PhD

President of Quanterix and Diagnostics


William Geist

Chief Operating Officer


Michael Doyle

Chief Financial Officer


Mark Roskey, PhD

Senior Vice President, Strategic Partnerships


David Duffy, PhD

Vice President, Research and Chief Technology Officer


Denise Chittick

Chief Human Resources Officer


Dawn R. Mattoon, PhD

Senior Vice President, Clinical Diagnostics


Richard Haigh, PhD

Senior Vice President, Research Products


John Fry, JD

General Counsel and Corporate Secretary


Brian Keane, JD

Senior Vice President and Senior Legal Counsel


Gerrit Smith

Senior Vice President of Operations


Kristine Klinger

Vice President, Enterprise Program Management Office


Kevin Hrusovsky

Chairman and Chief Executive Officer


Martin Madaus, PhD

Chief Operations Officer, Sherlock Biosciences, Inc.


Keith L. Crandell

Co-Founder & Managing Director, ARCH Venture Partners


David Walt, PhD

Senior Investigator, Brigham and Women’s Hospital, Department of Pathology, Core Faculty Member-Wyss Institute, Harvard Medical School at Harvard University


Paul Meister

Co-founder and Chief Executive Officer, Liberty Lane Partners, LLC


Marijn Dekkers

Chairman of Novalis LifeSciences


Sarah Hlavinka

Senior Vice President and General Counsel, Itron


Laurie Olson

Former Executive Vice President of Strategy and Commercial Operations at Pfizer, Inc.

Open Positions

Development

Senior Program Manager / Program Manager

Billerica, MA

Senior Program Manager / Program Manager

Remote

Distribution

Manager, Materials and Logistics

Billerica, MA

Engineering

Mechanical Engineering Coop (Spring 2020)

Billerica, MA

Mechanical Engineering Coop (Spring 2020)

Gothenberg, Sweden

Field Service

Field Service Engineer – Southern Germany

Tubingen, Germany

Field Service Engineer – Milan

Milan, Italy

Field Service Engineer – Gothenberg

Gothenberg, Sweden
Measure biomarkers at lower levels than ever before

Reverse Phase Protein Array

With Simoa Senstivity™, Quanterix’ Planar Array Technology now gives researchers an incredibly simple, flexible, robust, and sensitive multiplex immunoassay platform for measuring biomarkers in most common sample types.

  • Proprietary, high-precision, digital nanofluidic antibody deposition
  • Unique spot design
  • Reaction kinetics optimized by fluid dynamics
  • Optimized image quality & dynamic range
Measure biomarkers at lower levels than ever before

SIMOA® Bead Technology

Quanterix’ digital biomarker detection technology, Simoa®, is changing the way in which the biology of health and disease is studied by giving researchers the ability to examine critical proteins and nucleic acids, at ultra low – even baseline – levels, in most common sample types.

  • First of its kind detection capabilities
  • Detect biomarkers at femtogram levels
  • See results in record time
download brochure
How it works

A high level look at a Simoa Bead-based assay, from development to data analysis.

1

Paramagnetic particles coupled with antibodies designed to bind to specific targets are added to the sample.

Carousel Image 1
2

Detection antibodies – capable of generating fluorescent product – are added.

Carousel Image 2
3

The objective is to form an immunocomplex consisting of the bead, bound protein, and detection antibody.

Carousel Image 3
4

4 Detection antibodies – capable of generating fluorescent product – are added.

Measure biomarkers at lower levels than ever before

SIMOA® Planar Array

An incredibly simple, flexible, robust, and ultra-sensitive immunoassay platform for measuring up to 10-plex biomarkers. Its unique capabilities are designed specifically to address many of today’s unmet needs in immuno-oncology and other research areas.

  • Proprietary, high-precision, digital nanofluidic antibody deposition
  • Reaction kinetics optimized by fluid dynamics
  • Optimized image quality and dynamic range
download brochure
How it works

A high level look at a Simoa Planar Array assay, from initiation to imaging.

1

96-well plates are spotted at the factory with the target analyte(s) of interest

2

Diluted samples and standards added to each well and the plates are to create a unique surface chemistry and “vortex” effect

3

Biotinylated detection antibodies are added to form the other half of the immunocomplex “sandwich”

4

4 Diluted samples and standards added to each well and the plates are to create a unique surface chemistry and “vortex” effect

Scientific Principle of Single Molecule Array Technology

Single-molecule analysis provides a resolution that simply cannot be obtained with bulk ensemble measurements. Single molecule measurements are digital in nature:

Each molecule generates a signal that can be counted. It is much easier to measure the presence or absence of signal than to detect the absolute amount of signal — that is, counting is easier than integrating.

Quanterix has developed an approach for detecting thousands of single protein molecules simultaneously. Using the same reagents as a conventional ELISA, this method has been used to measure proteins in a variety of different matrices at femtomolar concentrations. This approach makes use of arrays of femtoliter-sized reaction chambers, which are termed single-molecule arrays (SimoaTM), that can isolate and detect single enzyme molecules. Because the array volumes are approximately 2 billion times smaller than a conventional ELISA, a rapid buildup of fluorescent product is generated if a labeled protein is present. With diffusion defeated, this high local concentration of product can be readily observed. Only a single molecule is needed to reach the detection limit.

Quanterix Iceberg Image

The Evolution of the Immunoassay

Revolutionizing new discoveries with ultra-sensitive detection. Enable detection of thousands more targets for drug development, efficacy and safety.

learn more
Quanterix Iceberg Image

Leverage Simoa for PK/PD, Efficacy, Safety and Target Engagement with the Highest Possible Sensitivity.

With the Simoa® Accelerator Laboratory as your pharma service technology solution of choice, you can expand the limits of biomarker exploration and dramatically accelerate the timeline to drug approvals.

The Simoa Accelerator Laboratory is a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. Our state-of-the-art facility includes a CLIA-certified lab and puts the power of groundbreaking Simoa technology to work to achieve research objectives for over 160 pharma and academic customers from all over the globe. As the innovators of the Simoa platform, the Accelerator Laboratory has completed more than 400 Simoa projects and well over 100,000 samples run to date – more than any other lab in the world.

Quanterix’ team of dedicated scientists offer the greatest depth of instrument experience and ultra-sensitive assay development – all the way through manufacturing – giving you instant access to Simoa technology. From expert and rapid development of custom assay kits, to selection of best antibody pairs, to running sample sets of any size, The Simoa Accelerator Lab treats every project with individualized attention to help your organization achieve its research and development goals efficiently and cost-effectively.

Why Choose Simoa Laboratory:

  • CLIA-Certified Laboratory
  • Offers the technology for single-plex and multiplex detection of proteins and nucleic acids, at ultra-sensitive levels
  • Provides the ability to use your proprietary antibodies/reagents or one of our extensive range of commercially-available assays
  • Infrastructure allows scalability to handle sample sets from one plate to thousands of samples
  • Develops robust SOPs and LIMS for project/sample tracking
  • Delivers quick turn-around with the flexibility to adjust project scope
  • Onsite assay development training available through a comprehensive, 4-day program

Already Working With Our Accelerator Team?

SIMOA Accelerator Leadership Team

Mark Roskey, Ph.D.

Senior Vice President, Commercial & Assays

David Hanlon, Ph.D.

Vice President, Accelerator and Pharma Services 2

Dan Sikkema, Ph.D.

Vice President, Accelerator and 3Pharma Services

Mary Ellen Cortizas, , JD

Vice President 4

Mark Roskey, Ph.D. 2

Vice President, Accelerator and Pharma Services 5

meet the team

SIMOA® HD-X Analyzer

Introducing the world’s most sensitive, fully automated immunoassay platform with multiplexing and custom assay capability

request a quote

HD-X Analyzer™ tab thumbnail

HD-X Analyzer™

Introducing the world’s most sensitive, fully automated immunoassay platform with multiplexing and custom assay capability.

HD-X Analyzer™ tab thumbnail

1000x

Up to 1000x greater sensitivity

6 in 1

Up to 6 biomarkers in a single assay

80+

Compatible with 80+ assays

request a quote
SP-X Imaging and Analysis System™ tab thumbnail

SP-X Imaging and Analysis System™

Unleashing the power of next-generation Simoa® Planar Array technology for robust multiplex biomarker detection – even at healthy baseline levels.

SP-X Imaging and Analysis System™ tab thumbnail

1000x

Up to 1000x greater sensitivity

10 in 1

Up to 10 biomarkers in a single assay

100+

Compatible with 100+ assays

request a quote
SR-X™ Biomarker Detection System tab thumbnail

SR-X™ Biomarker Detection System

Offers researchers access to ultra-sensitive biomarker detection capabilities in a compact and affordable system.

SR-X™ Biomarker Detection System tab thumbnail

1000x

Up to 1000x greater sensitivity

6 in 1

Up to 6 biomarkers in a single assay

30+

Compatible with 30+ assays

request a quote
2470 Arrayer tab thumbnail

2470 Arrayer

Produces high quality microarrays of DNA, proteins, cell lysates and a variety of other samples using its proprietary soft touch deposition technology.

2470 Arrayer tab thumbnail

Flexible

Unmatched sample flexibility

Versatile

Prints on a variety of surfaces

Quality

High density printing for accuracy

request a quote

asdasdasd

asdasdasdasd asd asd asd

learn more

Ready to take your biomarker research to the next level?

request a quote
products

Quanterix Instruments

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet.

SIMOA HD-X ANALYZER

Delivering Ultrasensitive Biomarker Measurement You Can Count On.

The latest model is a fully automated Simoa bead-based immunoassay platform. HD-X delivers major productivity improvements, greater user flexibility, unparalleled sensitivity, and best-in-class assay performance across a broad assay menu to empower biomarker research and accelerate drug development.

SIMOA SP-X

Single molecule detection in a benchtop instrument

Access Simoa-sensitive biomarker detection capabilities using the Simoa bead platform, in a compact, affordable system.

SIMOA SR-X

Single molecule detection in a benchtop instrument

Access Simoa-sensitive biomarker detection capabilities using the Simoa bead platform, in a compact, affordable system.

SIMOA 2470 Microarrayer

Quality, Reliability, Flexibility and True Walk-Away Automation in Mind

Produces high quality microarrays of DNA, proteins, cell lysates and a variety of other samples using its proprietary soft touch deposition technology.